All PlansCoverageHigh impact
Medical Policy and Coding Updates - August 2026
Premera Blue Cross·WA · Oncology, Radiation Oncology, Genetics +2 more·Medical Policy
Effective date
Nov 15, 2026
We identified it
Aug 6, 2026
Summary
This comprehensive August 2026 policy update from Carelon Medical Benefits Management affects genetic testing, somatic tumor testing, radiation oncology, and antipsychotic medications effective November 15, 2026. Major changes include expanded coverage for liquid biopsy testing in multiple cancer types, new non-medical necessity designations for specific tests, revised radiation oncology guidelines for non-malignant conditions, and updated criteria for hematologic malignancy testing. Billing teams must update prior authorization requirements, coverage determination logic, and clinical appropriateness screening across oncology, genetic testing, and radiation oncology services.
Action Required
By October 31, 2026: (1) Billing and clinical operations teams must update the billing system to reflect all coverage expansions and non-medical necessity determinations outlined in the genetic testing and somatic tumor testing sections, including new coverage for liquid biopsy tests in breast carcinoma (stages IIB-IIIC and metastatic), prostate carcinoma, and hematologic malignancies. (2) Update prior authorization rules to require medical necessity demonstration for all test components in genetic liquid biopsy and somatic tumor testing per revised general criteria. (3) Create new authorization denials for specified non-covered services including: RNA fusion/expression/whole transcriptome analysis using ctRNA, ctHPV DNA testing in oropharyngeal carcinoma, whole exome/genome/transcriptome analysis (WES/WGS/WTA), somatic testing of NIFTP, and radiation therapy for osteoarthritis, neovascular age-related macular degeneration, and refractory ventricular tachycardia. (4) Update radiation oncology authorization templates to reflect new guidelines for radiation therapy in select non-malignant vascular, inflammatory, fibrotic, and neurologic conditions. (5) Implement new coverage criteria additions for Oncotype DX (expanded to premenopausal <50 years), EndoPredict, MGMT promoter methylation, PIK3CA testing (colorectal), and expanded KRAS/niraparib/talazoparib criteria (prostate cancer). (6) Notify all oncology, radiation oncology, and genetic testing providers of the November 15, 2026 effective date through provider bulletins. (7) Configure system alerts for claims submitted before November 15, 2026 using old criteria to prevent processing errors. Failure to update authorization logic will result in inappropriate claim denials or approvals inconsistent with new clinical appropriateness guidelines.